Trial Profile

A Phase 2 study of 9MW2821 for the indication of esophageal carcinoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bulumtatug Furvedotin (Primary)
Indications Carcinoma; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

23 Mar 2024 New trial record
19 Mar 2024 According to a Mabwell media release, the phase II clinical study for the indication of esophageal carcinoma will continue enrollment and evaluation, and communication for the initiation of phase III clinical study will be expedited.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com